by Eric Christianson | Dec 17, 2023 | Endocrine Medication and Disease State Clinical Pearls
Semaglutide products have been popping up in news headlines recently, and not because of their continued popularity as effective weight loss medications. Data from poison control centers across the country indicates a drastic increase over the past year in calls...
by Eric Christianson | Nov 19, 2023 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls
Weight loss has been an essential area in which many pharmaceutical companies have made interventions by providing effective medications that can assist patients dealing with obesity. In this article, we will compare the newly approved weight loss medication Zepbound...
by Eric Christianson | Nov 15, 2023 | Gastrointestinal Medication and Disease State Clinical Pearls
This article is going to compare Wegovy versus Ozempic, two different brand-name medications that share the same active ingredient: semaglutide. Both medications are subcutaneous injections, and both are administered once per week using pen injector devices. The...
by Eric Christianson | Aug 9, 2023 | Clinical Pharmacy News and New Drug Updates, Endocrine Medication and Disease State Clinical Pearls
There’s always this voice in the back of my head that always cautions me that all that glitters is not gold. After being heralded as the next savior in weight loss by the media, the GLP-1 Agonists/GIP agonists have come under more scrutiny lately in the news. A...
by Eric Christianson | Mar 3, 2021 | Endocrine Medication and Disease State Clinical Pearls, Medication and Disease State Clinical Pearls For Pharmacists
Obesity is a major risk factor for many comorbidities (hypertension, dyslipidemia, osteoarthritis, sleep apnea, heart disease, type 2 diabetes) and increases all-cause and cardiovascular mortality. With over 40% of Americans qualifying as obese (body mass index ≥30...
